ESG Strategies & Goals

With the philosophy of "Better science, Better lives," we envision becoming a world-class innovative biopharmaceutical company, and research and develop innovative drugs in the spirit of sustainable development. In addition, we follow the framework of Access to Medicine Index 2018 to formulate strategies and guidelines to take the enhancement of “accessibility,” “affordability” and “availability” as our core concept and commitment.

Goal & Vision

• Vision：

  Transform innovative science into medical solutions that bring value to patients, addressing unmet medical needs.

• Goal：

  Achieve universal health coverage and promote health equity, helping all people access medicines and creating shared value for patients.

Exercising Core competencies to practice SDGs

The Sustainable Project combines the upstream, midstream, and downstream of the pharmaceutical industry to leverage its core competencies in new drug development, jointly addressing the three major ESG sustainability issues and creating shared value for patients, promoting the practice of sustainable health and well-being SDG3.
In order to meet the medical needs of rare disease patients worldwide, the sustainable issues addressing include environmental sustainability SDG3, SDG12, SDG13; product innovation SDG9, SDG17; human capital management SDG5, SDG8; patient acceptance and affordability SDG3, SDG9, SDG17; business ethics SDG3, SDG16, SDG17; product quality and safety SDG3, SDG9, SDG17; patient health and engagement SDG3, SDG9, SDG17. Through these sustainable actions, we will have a positive impact on society, patients, and the pharmaceutical industry, and continue to promote the practice of sustainable development goals.

As a science-oriented company focusing on innovative biopharmaceuticals, we start from the UN Sustainable Development Goal (SDG) 3: health and well-being as the core.Our sustainable development goals also integrated the Sustainability Accounting Standard Board (SASB) standards for the biotechnology pharmaceuticals industry, GRI standards, the United Nations Global Covenant, and the Access to Medicine Index with our business operation and strategy. Therefore, we also promote the economy's ecological balance and sustainable development, society, and the environment. We will continue to build a new biopharmaceutical company that is innovative, trustworthy and respectable by patients and to maximize human health and well-being.

Our sustainable development strategy is based on the core concept of SDG3, and we integrate ESG aspects at value chain stages, addressing significant issues aligned with：

• In Environment ,there is simultaneous response: SDG3, 12, and 13
• In Society, there is a simultaneous response: SDG3, 5, 8, 9, 16, and 17
• In Governance, there is a simultaneous response: SDG3, 16, and 17